How long the effect actually lasts — and why the numbers conflict

'How long will this last?' is the question most patients ask first — and the honest answer is considerably more encouraging than the figure that appears in many clinical summaries.

A 2024 cross-sectional study of 105 patients (149 knees) asked people directly how long they felt benefit after a single intra-articular HA injection. The mean self-reported duration of effectiveness was 48.2 weeks — roughly 11 months. That figure carries real variation: the standard deviation was ±24.8 weeks, meaning some patients reported benefit well beyond a year while others fell noticeably short. Individual response is genuinely wide, and that spread matters as much as the average.

Yet most pharmacological overviews and guideline summaries quote 3–6 months. Both figures are accurate; they are measuring different things. Controlled trials typically assess outcomes at fixed endpoints — often 12 or 26 weeks — because that is when funding cycles end and papers are written. When the trial stops collecting data at six months, it tells you nothing about whether the patient's pain stayed lower at month eight or ten. Real-world studies that ask patients retrospectively when their symptoms returned produce a longer number, because they capture the full arc of benefit rather than a snapshot.

The practical implication is straightforward: the 3–6 month window reflects when trials typically measure, not when benefit typically ends. A single injection's clinical benefit commonly peaks around four to six weeks post-injection, then gradually tapers — but for many patients in observational data, that tapering extends well into the second half of the year.

Which patients see the clearest benefit

Not every patient responds equally, and the evidence points to several variables that specialists weigh when assessing likely benefit — the most influential being how structurally advanced the osteoarthritis has become.

The role of Kellgren-Lawrence grade

Kellgren-Lawrence (KL) grading is the standard radiographic scale for knee OA severity. Grades 1–2 reflect mild change — minor osteophyte formation or slight joint-space narrowing — while grade 3 indicates moderate structural damage with more marked narrowing. Grade 4 represents severe, end-stage change, often described as bone-on-bone contact. Across every reviewed dataset, KL 1–3 patients show meaningfully better outcomes after single-injection HA than those with KL grade 4 disease. In one prospective study using Synvisc-One®, improvement in KL grade 1 patients was significantly stronger than in grades 2 or 3 over 52 weeks — suggesting that even within the favourable range, earlier disease responds best.

A satisfaction analysis of patients receiving a single injection of HANOX-M-XL (a mannitol-modified cross-linked HA) found that 88.7% of patients reported being satisfied overall. That headline figure, however, drops markedly among those with KL grade 4 or elevated BMI — a reminder that population-level averages can obscure meaningful subgroup differences. Multivariate analysis in the same dataset identified older age, KL grade below 4, absence of a simultaneous corticosteroid injection, and longer duration of effectiveness as independent predictors of satisfaction.

Four predictors of shorter duration

A separate 2024 cross-sectional study identified four independent factors associated with shorter duration of effectiveness in multivariate analysis:

• BMI above 27.5 kg/m²
• Multicompartmental joint involvement (more than one compartment affected)
• More than three prior viscosupplement courses
• Sedentary lifestyle

None of these factors is an absolute contraindication, but each reduces expected benefit. A patient with several of these characteristics should approach single-injection HA with calibrated expectations.

One further methodological point is worth noting: meta-analyses that exclude patients with grade 4 disease produce substantially higher efficacy estimates than those including the full range of severity. Published efficacy figures may therefore overstate likely benefit for unselected populations in clinical practice.

The interaction of KL grade, BMI, lifestyle, and prior treatment history is precisely why a blanket answer on HA suitability is unreliable. An assessment that includes weight-bearing imaging and a clinical review of these variables is the appropriate starting point for any individual considering this option.

Single injection versus multiple injections — what the comparisons show

The instinct to assume more injections means better results is understandable — but the evidence does not consistently support it, and the picture is more complicated than injection count alone.

A systematic review of 11 comparative studies found no consistent difference in patient-reported outcomes between single and multiple injection formulations; five-injection regimens were not shown to be superior to three-injection regimens. A different meta-analysis, however, reached the opposite conclusion: regimens of two to four injections, and those of five or more, each provided statistically significant pain relief over intra-articular saline — while single injections did not reach significance. Both bodies of work exist in the current literature, and neither has been definitively superseded.

A direct head-to-head trial of 54 patients with KL grade II–III disease adds a further twist. Participants randomised to a single injection of cross-linked NASHA (Durolane®) showed significantly better WOMAC scores at week 26 than those receiving a five-injection course of standard HA (Go-ON®), alongside lower analgesic use and reduced overall treatment cost.

That trial illustrates the central confounder in this debate: comparing a cross-linked, high-molecular-weight single-injection product against a standard multi-injection formulation is not a clean test of injection number. It conflates two separate variables — dosing schedule and product formulation — making it impossible to isolate which factor drove the outcome. Cross-linked and high-molecular-weight products behave differently in the joint from standard HA, independent of how many injections deliver them.

The honest summary is that the relevant clinical question is not simply 'one injection or several?' but 'which product, at which grade of disease, in which patient?' — a determination that depends on formulation characteristics as much as scheduling.

Evidence in more advanced knee OA — a bridge, not a cure

Severe osteoarthritis — broadly corresponding to KL grade 4 — has long been treated as the outer limit of HA injection benefit, and sections 1 and 2 explain why that caution exists. A 2026 prospective study from Russia, however, adds an important nuance for a specific subgroup: patients on a total knee arthroplasty (TKA) waiting list who still need their symptoms managed in the interim.

In that study of 86 patients with severe knee OA, a single injection of cross-linked HA (Flexotron Cross, 60 mg) added to standard therapy produced a 53.7% reduction in median VAS pain scores and a 47.4% reduction in WOMAC total scores at 24 weeks versus baseline. Superiority over standard therapy alone emerged from week 8 onward and was maintained across the observation period.

What this does not mean is equally important. The patients here were not being treated with any expectation of reversing structural damage — that is not a realistic goal in late-stage disease. The purpose was symptom relief and functional improvement while awaiting or considering surgery. In that framing, a clinically meaningful reduction in pain and disability over six months is a worthwhile outcome in its own right.

This is what clinicians mean by a bridge strategy: not a substitute for surgical planning, but a tool that may support quality of life and day-to-day function during a waiting period. Whether it is appropriate for any individual at this stage of disease is a question for specialist assessment, accounting for symptom burden, comorbidities, and surgical timeline.

What the evidence does not yet answer

Several clinically relevant questions remain genuinely open, and being clear about them helps set realistic expectations.

Injection technique. Ultrasound guidance is broadly recommended to improve accuracy, particularly in higher-BMI patients where landmark-based placement is less reliable. What the single-injection literature has not yet established is how large that accuracy advantage translates into in terms of measurable clinical outcomes.

Follow-up duration. Most trials set their primary endpoints at 26 weeks, and the best available long-term observation reaches 52 weeks. What happens to symptom scores beyond that point — and whether initial responders retain meaningful benefit — has not been adequately characterised for single-injection products specifically.

Structural effects. Whether single-injection HA slows cartilage loss or modifies the structural course of osteoarthritis is not established. Evidence of symptom relief does not imply tissue preservation, and the two should not be conflated.

Combination approaches. HA combined with PRP shows early promise across several outcome domains, but dedicated RCT data for single co-injection protocols remain sparse.

Outcome measurement. Duration-of-effect figures, including the 48-week mean discussed earlier, come from patient self-report. Objective functional endpoints measured over extended follow-up are still scarce — which means the real-world picture is encouraging but not yet fully verified.

Using this evidence when weighing your options

Taken together, the evidence positions single-injection HA as a more durable and better-characterised option than many guideline summaries imply — while making clear that who receives it matters at least as much as what is injected.

The patients most likely to benefit are those with KL grade 1–3 disease, a BMI below 27.5 kg/m², no more than three prior viscosupplementation courses, and an active rather than sedentary lifestyle. Where these factors align, the combination of meaningful symptom relief and a duration measured in months rather than weeks represents a clinically useful outcome. Where they do not — particularly in more structurally advanced or higher-BMI patients — expectations need to be calibrated accordingly.

Formulation is also worth raising with a specialist. Cross-linked, higher-molecular-weight products behave differently from standard HA preparations, and that distinction has a direct bearing on how published studies should be compared and which product might be most appropriate for a given clinical profile.

For patients with more advanced disease, single-injection HA may still provide worthwhile symptom relief as a bridge strategy, but it should be framed as symptom management rather than a primary treatment approach.

None of this translates into a universal recommendation — individual suitability depends on imaging to establish KL grade and compartment involvement, alongside a full clinical assessment. If you are weighing whether this option fits your situation, a structured specialist assessment is the appropriate starting point.

1. [1] A Cross-Sectional Study of Factors Predicting the Duration of the Efficacy of Viscosupplementation in Knee Osteoarthritis. (2024). https://doi.org/10.3390/jcm13071949 https://doi.org/10.3390/jcm13071949
2. [2] Predictors of Satisfaction in Patients with Knee OA Treated with a Single Injection of Mannitol-Modified Crosslinked Hyaluronate Derivative. (2024). https://doi.org/10.3390/jcm13185372 https://doi.org/10.3390/jcm13185372
3. [3] Improvement in condition-specific and generic quality of life outcomes following single intra-articular viscosupplementation injection. (2022). https://doi.org/10.1016/j.jcot.2022.101828 https://doi.org/10.1016/j.jcot.2022.101828
4. [4] Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized HA in a Single Injection versus Five Injections of Standard HA. (2017). https://doi.org/10.3390/ijms18030658 https://doi.org/10.3390/ijms18030658